A large new study suggests that GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, may significantly reduce the risk of breast cancer. The findings were published in the journal JCO Oncology Practice on June 2 and presented at the 2026 American Society of Clinical Oncology Annual Meeting.
Researchers at the Penn Medicine health system studied electronic health records from 111,646 women between the ages of 45 and 80, all of whom had a body mass index (BMI) of 25 or higher and had received breast imaging between January 2022 and June 2025. Women who were taking GLP-1 medications were approximately 30 percent less likely to develop breast cancer than women who were not taking the drugs.
Scientists are excited by the results but urge caution. The study is observational, which means it looked at existing health records rather than running a controlled experiment. This means researchers cannot yet say for certain that GLP-1 drugs directly cause the reduction in breast cancer risk.
The findings add to growing evidence that GLP-1 medications may offer health benefits beyond weight loss. Researchers are now calling for dedicated clinical trials to investigate whether these drugs could be used as a strategy to prevent breast cancer in women at high risk. The results may reshape how doctors think about prescribing these medicines.
A substantial observational study published in JCO Oncology Practice and presented at the 2026 ASCO Annual Meeting has added a striking new dimension to the scientific profile of GLP-1 receptor agonists. The Penn Medicine retrospective analysis of 111,646 women aged 45 to 80, all with a BMI of 25 or higher and breast imaging on record between January 2022 and June 2025, found that GLP-1 drug users were approximately 30 percent less likely to develop breast cancer during the observation period compared to non-users with similar baseline characteristics.
GLP-1 receptor agonists, including semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), were originally developed to manage type 2 diabetes. Their capacity to reduce body weight significantly has already made them among the most commercially successful drug classes in recent pharmaceutical history. Excess body fat is a well-established risk factor for breast cancer through several pathways, including elevated estrogen production from fatty tissue, chronic inflammation, and insulin resistance, all of which GLP-1 drugs appear to address.
The study's primary limitation is its retrospective observational design, which cannot establish a causal relationship. Women who take GLP-1 medications may differ from non-users in ways that are difficult to control for, including greater engagement with preventive health care and different metabolic profiles. The researchers acknowledge this and present the findings explicitly as hypothesis-generating rather than practice-changing.
Nevertheless, the study has attracted significant attention from oncologists and endocrinologists, several of whom have called for randomized controlled trials to test GLP-1 drugs specifically as a cancer prevention agent in high-risk populations. If the 30 percent risk reduction is confirmed in such trials, GLP-1 drugs could become one of the most impactful cancer prevention tools added to clinical practice in recent decades, potentially shifting prescribing decisions for millions of women worldwide.
The intersection of metabolic pharmacology and oncology claimed fresh scientific territory at the 2026 ASCO Annual Meeting with the presentation of a Penn Medicine retrospective cohort study, simultaneously published in JCO Oncology Practice, demonstrating a 30 percent reduction in breast cancer incidence among GLP-1 receptor agonist users in a sample of 111,646 women aged 45 to 80, all with BMI at or above 25. The magnitude of the association, if it survives rigorous replication and causal scrutiny, would position GLP-1 agonists as candidate first-line chemopreventive agents in a population currently underserved by pharmacological prevention beyond selective estrogen receptor modulators and aromatase inhibitors in specific high-risk subgroups.
The biological plausibility of a GLP-1 anti-neoplastic mechanism is supported by several converging lines of evidence. Adipose tissue functions as an active endocrine organ, secreting pro-inflammatory adipokines, elevating circulating estrogen via peripheral aromatization, and generating progressive hyperinsulinemia through insulin resistance. Each of these pathways independently elevates breast cancer risk in post-menopausal women, and GLP-1 agonists disrupt all three through their combined effects on adiposity, glycemic control, and inflammatory cytokine profiles. Supplementary in vitro and rodent studies have demonstrated GLP-1 receptor expression in breast epithelial tissue, with direct receptor activation associated with anti-proliferative signaling that may operate independently of weight reduction.
The study's observational architecture imposes significant interpretive limits. The Penn Medicine cohort is drawn from a single health system concentrated in the northeastern United States, constraining generalizability across the demographic, racial, and socioeconomic strata where breast cancer incidence and GLP-1 prescription patterns differ substantially. Residual confounding remains the principal methodological concern: GLP-1 users in observational datasets systematically differ from non-users in health-seeking behavior, preventive care access, baseline metabolic disease severity, and lifestyle covariates that are difficult to exhaust even with sophisticated propensity-score adjustment. The 30 percent relative risk reduction, while striking in magnitude, cannot be disentangled from these unmeasured factors without a prospective intervention design.
The clinical and commercial implications of a confirmed effect would be transformative. The breast cancer prevention market is currently dominated by tamoxifen and aromatase inhibitors, both carrying tolerability burdens that substantially limit uptake even among women with objectively elevated risk profiles. GLP-1 agonists, by contrast, are already prescribed at scale for metabolic indications, carry multi-year safety data from large cardiovascular outcomes trials, and could enter prevention trials without the consent friction associated with cancer-specific chemoprevention in lower-risk individuals. Shares in Novo Nordisk and Eli Lilly advanced on the ASCO presentation, and at least three contract research organizations reported accelerated trial design inquiries, suggesting financial markets have already begun pricing in the optionality of a confirmed oncological indication even in the absence of prospective evidence.
A study of 111,646 women published in JCO Oncology Practice and presented at the 2026 ASCO Annual Meeting found that those taking GLP-1 drugs such as Ozempic and Wegovy were about 30 percent less likely to develop breast cancer. The research drew on electronic health records from the Penn Medicine system, covering women aged 45 to 80 with a body mass index of 25 or higher. Scientists call the findings hypothesis-generating and say clinical trials are now needed to investigate GLP-1 drugs as a breast cancer prevention strategy.

Scientists did a big study about medicines called GLP-1 drugs. Famous examples are Ozempic and Wegovy. Many people take these medicines to lose weight.
The scientists looked at health records from over 111,000 women. The women were between 45 and 80 years old. Some women took GLP-1 medicines and some did not.
The scientists found something surprising. Women who took GLP-1 medicines got breast cancer much less often. They were about 30 percent less likely to get breast cancer.
The scientists say we need more studies to be sure. This study only looked at health records. We need special tests called clinical trials to know if these medicines can really prevent breast cancer.
1What are Ozempic and Wegovy?
2How many women were included in the study?
3How much less likely were GLP-1 users to get breast cancer?
4What kind of records did scientists look at?
5What do scientists say is needed to be more certain about the results?
6GLP-1 drugs like Ozempic are taken to help people lose weight.
7The study found GLP-1 users were more likely to get breast cancer.
8Scientists looked at records from women between 45 and 80 years old.
9Scientists say the study results are already 100 percent certain.
10Clinical trials are needed to confirm whether GLP-1 drugs can prevent breast cancer.
11Ozempic and Wegovy are examples of ___ drugs.
12Women on GLP-1 drugs were about ___ percent less likely to get breast cancer.
13Scientists say we need ___ trials to confirm the results.